Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Lantheus Holdings, Inc. received a consensus rating of "Moderate Buy" from eight brokerages, with a price target averaging $74.50.
• Insider transactions showed a significant sell-off, with 6.81 million shares worth approximately $382 million sold by insiders in the past 90 days.
• The company's stock has seen a 52-week range between $47.25 and $118.21, indicating volatility in its market performance.

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $74.50.

LNTH has been the topic of a number of analyst reports. William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the company a "neutral" rating in a research note on Wednesday, October 8th. Truist Financial set a $63.00 price target on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Lantheus in a research note on Wednesday, October 8th.

Lantheus Stock Up 2.6%

NASDAQ:LNTH opened at $56.52 on Thursday. The stock's fifty day moving average price is $53.91 and its two-hundred day moving average price is $73.87. Lantheus has a 52-week low of $47.25 and a 52-week high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 15.03 and a beta of 0.09.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. On average, analysts anticipate that Lantheus will post 6.01 EPS for the current year.

Insiders Place Their Bets

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of Lantheus

A number of large investors have recently made changes to their positions in the company. State of Michigan Retirement System increased its position in shares of Lantheus by 0.6% in the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 100 shares in the last quarter. Signaturefd LLC increased its holdings in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares in the last quarter. Intrust Bank NA increased its holdings in Lantheus by 2.9% during the 1st quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock worth $431,000 after purchasing an additional 125 shares in the last quarter. Focus Financial Network Inc. increased its holdings in Lantheus by 4.0% during the 2nd quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider's stock worth $293,000 after purchasing an additional 136 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock worth $653,000 after purchasing an additional 139 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.